76 related articles for article (PubMed ID: 23507588)
1. [Driver gene mutation and targeted therapy of lung cancer].
Mitsudomi T
Gan To Kagaku Ryoho; 2013 Mar; 40(3):285-90. PubMed ID: 23507588
[TBL] [Abstract][Full Text] [Related]
2. Personalized targeted therapy in advanced non-small cell lung cancer.
Ma PC
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
4. Successes and limitations of targeted cancer therapy in lung cancer.
Suda K; Mitsudomi T
Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
[TBL] [Abstract][Full Text] [Related]
6. Advances in target therapy for lung cancer.
Mitsudomi T
Jpn J Clin Oncol; 2010 Feb; 40(2):101-6. PubMed ID: 20031962
[TBL] [Abstract][Full Text] [Related]
7. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.
Mitsudomi T; Yatabe Y
Cancer Sci; 2007 Dec; 98(12):1817-24. PubMed ID: 17888036
[TBL] [Abstract][Full Text] [Related]
8. Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation.
Suda K; Tomizawa K; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
Lung Cancer; 2012 Jun; 76(3):292-9. PubMed ID: 22133747
[TBL] [Abstract][Full Text] [Related]
9. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer.
Yoshida T; Zhang G; Haura EB
Biochem Pharmacol; 2010 Sep; 80(5):613-23. PubMed ID: 20519133
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
11. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.
Suda K; Tomizawa K; Mitsudomi T
Cancer Metastasis Rev; 2010 Mar; 29(1):49-60. PubMed ID: 20108024
[TBL] [Abstract][Full Text] [Related]
12. Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.
Lee J; Ou SH
Discov Med; 2013 Aug; 16(86):7-14. PubMed ID: 23911227
[TBL] [Abstract][Full Text] [Related]
13. [Development of molecular targeted therapies in lung cancers].
Suda K; Mitsudomi T
Nihon Geka Gakkai Zasshi; 2014 May; 115(3):130-6. PubMed ID: 24946519
[TBL] [Abstract][Full Text] [Related]
14. From platinum compounds to targeted therapies in advanced thoracic malignancies.
Jakopovic M; Thomas A; Lopez-Chavez A
Anticancer Res; 2014 Jan; 34(1):477-82. PubMed ID: 24403504
[TBL] [Abstract][Full Text] [Related]
15. Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Ferrara MG; Di Noia V; D'Argento E; Vita E; Damiano P; Cannella A; Ribelli M; Pilotto S; Milella M; Tortora G; Bria E
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32397295
[TBL] [Abstract][Full Text] [Related]
16. Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.
Koga T; Suda K; Mitsudomi T
Cancer Sci; 2022 Mar; 113(3):815-827. PubMed ID: 34997674
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Therapy.
Rivera G; Wakelee HA
Cancer Treat Res; 2016; 170():183-202. PubMed ID: 27535395
[TBL] [Abstract][Full Text] [Related]
18. Current Landscape of Targeted Therapy in Lung Cancer.
Mayekar MK; Bivona TG
Clin Pharmacol Ther; 2017 Nov; 102(5):757-764. PubMed ID: 28786099
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer patients with an abnormal gene benefit from targeted therapy.
Printz C
Cancer; 2013 Oct; 119(20):3582. PubMed ID: 24101567
[No Abstract] [Full Text] [Related]
20. Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.
Berghoff AS; Bellosillo B; Caux C; de Langen A; Mazieres J; Normanno N; Preusser M; Provencio M; Rojo F; Wolf J; Zielinski CC
ESMO Open; 2019; 4(3):e000498. PubMed ID: 31297240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]